ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 80 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q1 2022. The put-call ratio across all filers is 4.85 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $337,598 | -15.7% | 432,818 | 0.0% | 0.00% | -50.0% |
| Q2 2023 | $400,356 | -15.1% | 432,818 | 0.0% | 0.00% | -20.0% |
| Q1 2023 | $471,771 | -25.3% | 432,818 | 0.0% | 0.01% | -28.6% |
| Q4 2022 | $631,914 | +35.9% | 432,818 | 0.0% | 0.01% | +16.7% |
| Q3 2022 | $465,000 | -36.8% | 432,818 | 0.0% | 0.01% | -25.0% |
| Q2 2022 | $736,000 | -17.5% | 432,818 | 0.0% | 0.01% | -11.1% |
| Q1 2022 | $892,000 | -45.0% | 432,818 | 0.0% | 0.01% | -43.8% |
| Q4 2021 | $1,623,000 | -27.5% | 432,818 | -0.0% | 0.02% | -33.3% |
| Q3 2021 | $2,238,000 | +21.4% | 432,921 | 0.0% | 0.02% | +20.0% |
| Q2 2021 | $1,844,000 | -19.8% | 432,921 | 0.0% | 0.02% | -31.0% |
| Q1 2021 | $2,299,000 | -1.5% | 432,921 | 0.0% | 0.03% | -12.1% |
| Q4 2020 | $2,333,000 | -32.5% | 432,921 | 0.0% | 0.03% | -44.1% |
| Q3 2020 | $3,455,000 | -22.1% | 432,921 | -2.3% | 0.06% | -34.4% |
| Q2 2020 | $4,434,000 | +308.7% | 442,921 | +11.0% | 0.09% | +181.2% |
| Q1 2020 | $1,085,000 | +28.7% | 398,853 | -43.2% | 0.03% | +45.5% |
| Q4 2019 | $843,000 | -20.5% | 702,575 | 0.0% | 0.02% | -26.7% |
| Q3 2019 | $1,061,000 | -62.5% | 702,575 | -0.3% | 0.03% | -66.3% |
| Q2 2019 | $2,832,000 | +130.4% | 704,472 | +146.6% | 0.09% | +122.5% |
| Q1 2019 | $1,229,000 | -4.4% | 285,722 | +27.9% | 0.04% | -18.4% |
| Q4 2018 | $1,285,000 | -57.6% | 223,430 | 0.0% | 0.05% | -52.4% |
| Q3 2018 | $3,030,000 | +4.8% | 223,430 | -8.2% | 0.10% | -5.5% |
| Q2 2018 | $2,890,000 | +5.7% | 243,430 | 0.0% | 0.11% | -1.8% |
| Q1 2018 | $2,734,000 | +30.8% | 243,430 | -22.2% | 0.11% | +30.6% |
| Q4 2017 | $2,090,000 | -20.5% | 312,930 | -2.5% | 0.08% | -25.4% |
| Q3 2017 | $2,629,000 | +192.1% | 321,050 | +60.1% | 0.11% | +185.0% |
| Q2 2017 | $900,000 | -18.6% | 200,525 | 0.0% | 0.04% | -20.0% |
| Q1 2017 | $1,105,000 | +36.1% | 200,525 | 0.0% | 0.05% | +22.0% |
| Q4 2016 | $812,000 | -65.1% | 200,525 | -39.3% | 0.04% | -65.8% |
| Q3 2016 | $2,327,000 | -36.6% | 330,125 | -26.7% | 0.12% | -40.6% |
| Q2 2016 | $3,672,000 | +125.3% | 450,525 | +124.7% | 0.20% | +104.0% |
| Q1 2016 | $1,630,000 | +7.7% | 200,525 | 0.0% | 0.10% | +3.1% |
| Q4 2015 | $1,514,000 | – | 200,525 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM ASSET MANAGEMENT LLC | 6,287,101 | $4,903,939 | 2.63% |
| Syncona Portfolio Ltd | 1,377,294 | $1,074,289 | 1.60% |
| MPM BioImpact LLC | 5,095,912 | $3,974,811 | 1.06% |
| NEA Management Company, LLC | 17,079,778 | $13,322,227 | 1.03% |
| TANG CAPITAL MANAGEMENT LLC | 5,166,954 | $4,030,224 | 0.57% |
| PFM Health Sciences, LP | 10,423,135 | $8,130,045 | 0.38% |
| Matrix Capital Management Company, LP | 38,974,185 | $30,399,864 | 0.36% |
| Long Focus Capital Management, LLC | 10,963,158 | $8,551,263 | 0.31% |
| Acuitas Investments, LLC | 479,764 | $374,216 | 0.22% |
| Endurant Capital Management LP | 311,944 | $243,316 | 0.22% |